<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39381876</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4636</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Arteriosclerosis, thrombosis, and vascular biology</Title><ISOAbbreviation>Arterioscler Thromb Vasc Biol</ISOAbbreviation></Journal><ArticleTitle>COVID-19 Is a Coronary Artery Disease Risk Equivalent and Exhibits a Genetic Interaction With ABO Blood Type.</ArticleTitle><Pagination><StartPage>2321</StartPage><EndPage>2333</EndPage><MedlinePgn>2321-2333</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/ATVBAHA.124.321001</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">COVID-19 is associated with acute risk of major adverse cardiac events (MACE), including myocardial infarction, stroke, and mortality (all-cause). However, the duration and underlying determinants of heightened risk of cardiovascular disease and MACE post-COVID-19 are not known.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Data from the UK Biobank was used to identify COVID-19 cases (n=10 005) who were positive for polymerase chain reaction (PCR<sup>+</sup>)-based tests for SARS-CoV-2 infection (n=8062) or received hospital-based <i>International Classification of Diseases version-10 (ICD-10</i>) codes for COVID-19 (n=1943) between February 1, 2020 and December 31, 2020. Population controls (n=217 730) and propensity score-matched controls (n=38 860) were also drawn from the UK Biobank during the same period. Proportional hazard models were used to evaluate COVID-19 for association with long-term (&gt;1000 days) risk of MACE and as a coronary artery disease risk equivalent. Additional analyses examined whether COVID-19 interacted with genetic determinants to affect the risk of MACE and its components.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The risk of MACE was elevated in COVID-19 cases at all levels of severity (HR, 2.09 [95% CI, 1.94-2.25]; <i>P</i>&lt;0.0005) and to a greater extent in cases hospitalized for COVID-19 (HR, 3.85 [95% CI, 3.51-4.24]; <i>P</i>&lt;0.0005). Hospitalization for COVID-19 represented a coronary artery disease risk equivalent since incident MACE risk among cases without history of cardiovascular disease was even higher than that observed in patients with cardiovascular disease without COVID-19 (HR, 1.21 [95% CI, 1.08-1.37]; <i>P</i>&lt;0.005). A significant genetic interaction was observed between the <i>ABO</i> locus and hospitalization for COVID-19 (<i>P</i><sub>interaction</sub>=0.01), with risk of thrombotic events being increased in subjects with non-O blood types (HR, 1.65 [95% CI, 1.29-2.09]; <i>P</i>=4.8×10<sup>-5</sup>) to a greater extent than subjects with blood type O (HR, 0.96 [95% CI, 0.66-1.39]; <i>P</i>=0.82).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Hospitalization for COVID-19 represents a coronary artery disease risk equivalent, with post-acute myocardial infarction and stroke risk particularly heightened in non-O blood types. These results may have important clinical implications and represent, to our knowledge, one of the first examples of a gene-pathogen exposure interaction for thrombotic events.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hilser</LastName><ForeName>James R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0001-5849-7839</Identifier><AffiliationInfo><Affiliation>Department of Population and Public Health Sciences (J.R.H., N.J.S., K.A., F.D.G., H.H., J.A.H., H.A.), Keck School of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Medicine (J.R.H., N.J.S., K.A., H.A.), Keck School of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spencer</LastName><ForeName>Neal J</ForeName><Initials>NJ</Initials><Identifier Source="ORCID">0009-0006-3911-2706</Identifier><AffiliationInfo><Affiliation>Department of Population and Public Health Sciences (J.R.H., N.J.S., K.A., F.D.G., H.H., J.A.H., H.A.), Keck School of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Medicine (J.R.H., N.J.S., K.A., H.A.), Keck School of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afshari</LastName><ForeName>Kimia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Population and Public Health Sciences (J.R.H., N.J.S., K.A., F.D.G., H.H., J.A.H., H.A.), Keck School of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Medicine (J.R.H., N.J.S., K.A., H.A.), Keck School of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilliland</LastName><ForeName>Frank D</ForeName><Initials>FD</Initials><Identifier Source="ORCID">0000-0002-9033-7269</Identifier><AffiliationInfo><Affiliation>Department of Population and Public Health Sciences (J.R.H., N.J.S., K.A., F.D.G., H.H., J.A.H., H.A.), Keck School of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Howard</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-3676-2707</Identifier><AffiliationInfo><Affiliation>Department of Population and Public Health Sciences (J.R.H., N.J.S., K.A., F.D.G., H.H., J.A.H., H.A.), Keck School of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deb</LastName><ForeName>Arjun</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0978-2611</Identifier><AffiliationInfo><Affiliation>Department of Medicine (A.D., A.J.L.), Keck School of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lusis</LastName><ForeName>Aldons J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0001-9013-0228</Identifier><AffiliationInfo><Affiliation>Department of Medicine (A.D., A.J.L.), Keck School of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Immunology, and Molecular Genetics (A.J.L.), David Geffen School of Medicine of UCLA, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics (A.J.L.), David Geffen School of Medicine of UCLA, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson Tang</LastName><ForeName>W H</ForeName><Initials>WH</Initials><Identifier Source="ORCID">0000-0002-8335-735X</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute (W.H.W.T., S.L.H.), Cleveland Clinic, OH.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute (W.H.W.T., S.L.H.), Cleveland Clinic, OH.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Microbiome and Human Health (W.H.W.T., S.L.H.), Cleveland Clinic, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartiala</LastName><ForeName>Jaana A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0003-4883-9318</Identifier><AffiliationInfo><Affiliation>Department of Population and Public Health Sciences (J.R.H., N.J.S., K.A., F.D.G., H.H., J.A.H., H.A.), Keck School of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hazen</LastName><ForeName>Stanley L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0001-7124-6639</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute (W.H.W.T., S.L.H.), Cleveland Clinic, OH.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute (W.H.W.T., S.L.H.), Cleveland Clinic, OH.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Microbiome and Human Health (W.H.W.T., S.L.H.), Cleveland Clinic, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Allayee</LastName><ForeName>Hooman</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-2384-5239</Identifier><AffiliationInfo><Affiliation>Department of Population and Public Health Sciences (J.R.H., N.J.S., K.A., F.D.G., H.H., J.A.H., H.A.), Keck School of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Medicine (J.R.H., N.J.S., K.A., H.A.), Keck School of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL148110</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL168493</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arterioscler Thromb Vasc Biol</MedlineTA><NlmUniqueID>9505803</NlmUniqueID><ISSNLinking>1079-5642</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000017">ABO Blood-Group System</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.1.-</RegistryNumber><NameOfSubstance UI="C000708573">ABO protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.1.-</RegistryNumber><NameOfSubstance UI="D005700">Galactosyltransferases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000017" MajorTopicYN="Y">ABO Blood-Group System</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005700" MajorTopicYN="N">Galactosyltransferases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">genetics</Keyword><Keyword MajorTopicYN="N">major adverse cardiac events</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword><Keyword MajorTopicYN="N">stroke</Keyword><Keyword MajorTopicYN="N">thrombosis</Keyword></KeywordList><CoiStatement>Dr Hazen reports being named as co-inventors on pending and issued patents held by the Cleveland Clinic relating to cardiovascular diagnostics and therapeutics. Dr Hazen also reports having received royalty payments for inventions or discoveries related to cardiovascular diagnostics or therapeutics from Cleveland Heart Laboratory, a fully owned subsidiary of Quest Diagnostics, and Procter &amp; Gamble. Dr Hazen is a paid consultant for Zehna Therapeutics and Proctor &amp; Gamble and has received research funds from Zehna Therapeutics, Proctor &amp; Gamble, Pfizer, and Roche Diagnostics. All other authors have no competing financial interests or personal relationships to declare related to the work reported in this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>22</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>7</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>5</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39381876</ArticleId><ArticleId IdType="mid">NIHMS2017887</ArticleId><ArticleId IdType="pmc">PMC11495539</ArticleId><ArticleId IdType="doi">10.1161/ATVBAHA.124.321001</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO COVID-19 Dashboard.
Geneva: World Health Organization; 2020. Accessed August 9, 2024. https://COVID19.who.int/</Citation></Reference><Reference><Citation>Giacca M, Shah AM. The pathological maelstrom of COVID-19 and cardiovascular disease. Nat Cardiovasc Res. 2022;1:200–210. doi: 10.1038/s44161-022-00029-5</Citation><ArticleIdList><ArticleId IdType="pubmed">39195986</ArticleId></ArticleIdList></Reference><Reference><Citation>Aleksova A, Fluca AL, Gagno G, Pierri A, Padoan L, Derin A, Moretti R, Noveska EA, Azzalini E, D’Errico S, et al. . Long-term effect of SARS-CoV-2 infection on cardiovascular outcomes and all-cause mortality. Life Sci. 2022;310:121018. doi: 10.1016/j.lfs.2022.121018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9561478</ArticleId><ArticleId IdType="pubmed">36183780</ArticleId></ArticleIdList></Reference><Reference><Citation>Nappi F, Nappi P, Gambardella I, Avtaar Singh SS. Thromboembolic disease and cardiac thrombotic complication in COVID-19: a systematic review. Metabolites. 2022;12:889. doi: 10.3390/metabo12100889</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9611930</ArticleId><ArticleId IdType="pubmed">36295791</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28:583–590. doi: 10.1038/s41591-022-01689-3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight R, Walker V, Ip S, Cooper JA, Bolton T, Keene S, Denholm R, Akbari A, Abbasizanjani H, Torabi F, et al. ; CVD-COVID-UK/COVID-IMPACT Consortium and the Longitudinal Health and Wellbeing COVID-19 National Core Study. Association of COVID-19 with major arterial and venous thrombotic diseases: a population-wide cohort study of 48 million adults in England and Wales. Circulation. 2022;146:892–906. doi: 10.1161/CIRCULATIONAHA.122.060785</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9484653</ArticleId><ArticleId IdType="pubmed">36121907</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu E, Xie Y, Al-Aly Z. Long-term neurologic outcomes of COVID-19. Nat Med. 2022;28:2406–2415. doi: 10.1038/s41591-022-02001-z</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9671811</ArticleId><ArticleId IdType="pubmed">36138154</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Narayan RK, Kumari C, Faiq MA, Kulandhasamy M, Kant K, Pareek V. SARS-CoV-2 cell entry receptor ACE2 mediated endothelial dysfunction leads to vascular thrombosis in COVID-19 patients. Med Hypotheses. 2020;145:110320. doi: 10.1016/j.mehy.2020.110320</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7525265</ArticleId><ArticleId IdType="pubmed">33032170</ArticleId></ArticleIdList></Reference><Reference><Citation>Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020;38:1504–1507. doi: 10.1016/j.ajem.2020.04.048</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165109</ArticleId><ArticleId IdType="pubmed">32317203</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17:259–260. doi: 10.1038/s41569-020-0360-5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095524</ArticleId><ArticleId IdType="pubmed">32139904</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020;14:247–250. doi: 10.1016/j.dsx.2020.03.013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102662</ArticleId><ArticleId IdType="pubmed">32247212</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17:543–558. doi: 10.1038/s41569-020-0413-9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7370876</ArticleId><ArticleId IdType="pubmed">32690910</ArticleId></ArticleIdList></Reference><Reference><Citation>Loffi M, Piccolo R, Regazzoni V, Di Tano G, Moschini L, Robba D, Quinzani F, Esposito G, Franzone A, Danzi GB. Coronary artery disease in patients hospitalised with Coronavirus disease 2019 (COVID-19) infection. Open Heart. 2020;7:e001428. doi: 10.1136/openhrt-2020-001428</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7684763</ArticleId><ArticleId IdType="pubmed">33229434</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nat Med. 2023;29:2347–2357. doi: 10.1038/s41591-023-02521-2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10504070</ArticleId><ArticleId IdType="pubmed">37605079</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks E, Crouch SR, Korda RJ, Stavreski B, Page K, Thurber KA, Grenfell R. Absolute risk of cardiovascular disease events, and blood pressure- and lipid-lowering therapy in Australia. Med J Aust. 2016;204:320. doi: 10.5694/mja15.01004</Citation><ArticleIdList><ArticleId IdType="pubmed">27125809</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew DP, Scott IA, Cullen L, French JK, Briffa TG, Tideman PA, Woodruffe S, Kerr A, Branagan M, Aylward PEG; NHFA/CSANZ ACS Guideline 2016 Executive Working Group. National Heart Foundation of Australia &amp; Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016. Heart Lung Circ. 2016;25:895–951. doi: 10.1016/j.hlc.2016.06.789</Citation><ArticleIdList><ArticleId IdType="pubmed">27476580</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al. . 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019;139:e1046–e1081. doi: 10.1161/CIR.0000000000000624</Citation><ArticleIdList><ArticleId IdType="pubmed">30565953</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, et al. . 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation. 2019;140:e563–e595. doi: 10.1161/CIR.0000000000000677</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8351755</ArticleId><ArticleId IdType="pubmed">30879339</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, Francis GA, Genest J, Grégoire J, Grover SA, et al. . 2021 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37:1129–1150. doi: 10.1016/j.cjca.2021.03.016</Citation><ArticleIdList><ArticleId IdType="pubmed">33781847</ArticleId></ArticleIdList></Reference><Reference><Citation>Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, et al. ; ESC National Cardiac Societies. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227–3337. doi: 10.1093/eurheartj/ehab484</Citation><ArticleIdList><ArticleId IdType="pubmed">34458905</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan JWC, Chew DP, Brieger D, Eikelboom J, Montalescot G, Ako J, Kim B-K, Quek DK, Aitken SJ, Chow CK, et al. . 2020 Asian Pacific Society of Cardiology consensus recommendations on antithrombotic management for high-risk chronic coronary syndrome. Eur Cardiol. 2021;16:e26. doi: 10.15420/ecr.2020.45</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8251506</ArticleId><ArticleId IdType="pubmed">34249148</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh N, Ference BA, Nicholls SJ, Navar AM, Chew DP, Kostner K, He B, Tse HF, Dalal J, Santoso A, et al. . Asian Pacific Society of Cardiology consensus recommendations on dyslipidaemia. Eur Cardiol. 2021;16:e54. doi: 10.15420/ecr.2021.36</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8728885</ArticleId><ArticleId IdType="pubmed">35024056</ArticleId></ArticleIdList></Reference><Reference><Citation>ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Das SR, Hilliard ME, Isaacs D, et al. ; on behalf of the American Diabetes Association. 10. Cardiovascular disease and risk management: standards of care in diabetes - 2023. Diabetes Care. 2023;46:S158–S190. doi: 10.2337/dc23-S010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9810475</ArticleId><ArticleId IdType="pubmed">36507632</ArticleId></ArticleIdList></Reference><Reference><Citation>Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234. doi: 10.1056/NEJM199807233390404</Citation><ArticleIdList><ArticleId IdType="pubmed">9673301</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Host Genetics Initiative. The COVID-19 Host Genetics Initiative. A second update on mapping the human genetic architecture of COVID-19. Nature. 2023;621:E7–E26. doi: 10.1038/s41586-023-06355-3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10482689</ArticleId><ArticleId IdType="pubmed">37674002</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilly MP, Li M, He J, Ferguson JF, Stylianou IM, Mehta NN, Burnett MS, Devaney JM, Knouff CW, Thompson JR, et al. ; Myocardial Infarction Genetics Consortium. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet. 2011;377:383–392. doi: 10.1016/S0140-6736(10)61996-4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3297116</ArticleId><ArticleId IdType="pubmed">21239051</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartiala JA, Han Y, Jia Q, Hilser JR, Huang P, Gukasyan J, Schwartzman WS, Cai Z, Biswas S, Trégouët D-A, et al. ; INVENT Consortium. Genome-wide analysis identifies novel susceptibility loci for myocardial infarction. Eur Heart J. 2021;42:919–933. doi: 10.1093/eurheartj/ehaa1040</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7936531</ArticleId><ArticleId IdType="pubmed">33532862</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, Fernández J, Prati D, Baselli G, Asselta R, et al. ; Severe Covid-19 GWAS Group. Genomewide association study of severe Covid-19 with respiratory failure. N Engl J Med. 2020;383:1522–1534. doi: 10.1056/NEJMoa2020283</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7315890</ArticleId><ArticleId IdType="pubmed">32558485</ArticleId></ArticleIdList></Reference><Reference><Citation>Goker H, Aladag Karakulak E, Demiroglu H, Ayaz Ceylan CM, Büyükaşik Y, Inkaya AC, Aksu S, Sayinalp N, Haznedaroğlu IC, Uzun O, et al. . The effects of blood group types on the risk of COVID-19 infection and its clinical outcome. Turk J Med Sci. 2020;50:679–683. doi: 10.3906/sag-2005-395</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7379446</ArticleId><ArticleId IdType="pubmed">32496734</ArticleId></ArticleIdList></Reference><Reference><Citation>Solmaz I, Arac S. ABO blood groups in COVID-19 patients; cross-sectional study. Int J Clin Pract. 2021;75:e13927. doi: 10.1111/ijcp.13927</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7883261</ArticleId><ArticleId IdType="pubmed">33296536</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel R, Bloch EM, Pirenne F, Al-Riyami AZ, Crowe E, Dau L, Land K, Townsend M, Jecko T, Rahimi-Levene N, et al. ; ISBT COVID-19 Working Group. ABO blood group and COVID-19: a review on behalf of the ISBT COVID-19 Working Group. Vox Sang. 2021;116:849–861. doi: 10.1111/vox.13076</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014128</ArticleId><ArticleId IdType="pubmed">33578447</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Latz CA, DeCarlo CS, Lee S, Png CYM, Kibrik P, Sung E, Alabi O, Dua A. Relationship between blood type and outcomes following COVID-19 infection. Semin Vasc Surg. 2021;34:125–131. doi: 10.1053/j.semvascsurg.2021.05.005</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8286549</ArticleId><ArticleId IdType="pubmed">34642032</ArticleId></ArticleIdList></Reference><Reference><Citation>Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delaneau O, O’Connell J, et al. . The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203–209. doi: 10.1038/s41586-018-0579-z</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6786975</ArticleId><ArticleId IdType="pubmed">30305743</ArticleId></ArticleIdList></Reference><Reference><Citation>McCaffrey DF, Ridgeway G, Morral AR. Propensity score estimation with boosted regression for evaluating causal effects in observational studies. Psychol Methods. 2004;9:403–425. doi: 10.1037/1082-989X.9.4.403</Citation><ArticleIdList><ArticleId IdType="pubmed">15598095</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekhon JS. Multivariate and propensity score matching software with automated balance optimization: the Matching package for R. J Stat Softw. 2011;42:1–52. doi: 10.18637/jss.v042.i07</Citation></Reference><Reference><Citation>Hilser JR, Han Y, Biswas S, Gukasyan J, Cai Z, Zhu R, Tang WHW, Deb A, Lusis AJ, Hartiala JA, et al. . Association of serum HDL-cholesterol and apolipoprotein A1 levels with risk of severe SARS-CoV-2 infection. J Lipid Res. 2021;62:100061. doi: 10.1016/j.jlr.2021.100061</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7923911</ArticleId><ArticleId IdType="pubmed">33667465</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y, Jia Q, Jahani PS, Hurrell BP, Pan C, Huang P, Gukasyan J, Woodward NC, Eskin E, Gilliland FD, et al. . Genome-wide analysis highlights contribution of immune system pathways to the genetic architecture of asthma. Nat Commun. 2020;11:1776. doi: 10.1038/s41467-020-15649-3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7160128</ArticleId><ArticleId IdType="pubmed">32296059</ArticleId></ArticleIdList></Reference><Reference><Citation>Groot HE, Villegas Sierra LE, Said MA, Lipsic E, Karper JC, van der Harst P. Genetically determined ABO blood group and its associations with health and disease. Arterioscler Thromb Vasc Biol. 2020;40:830–838. doi: 10.1161/ATVBAHA.119.313658</Citation><ArticleIdList><ArticleId IdType="pubmed">31969017</ArticleId></ArticleIdList></Reference><Reference><Citation>McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, et al. . A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316:1488–1491. doi: 10.1126/science.1142447</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2711874</ArticleId><ArticleId IdType="pubmed">17478681</ArticleId></ArticleIdList></Reference><Reference><Citation>Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, Jonasdottir A, Sigurdsson A, Baker A, Palsson A, et al. . A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316:1491–1493. doi: 10.1126/science.1142842</Citation><ArticleIdList><ArticleId IdType="pubmed">17478679</ArticleId></ArticleIdList></Reference><Reference><Citation>Tcheandjieu C, Zhu X, Hilliard AT, Clarke SL, Napolioni V, Ma S, Lee KM, Fang H, Chen F, Lu Y, et al. ; Regeneron Genetics Center. Large-scale genome-wide association study of coronary artery disease in genetically diverse populations. Nat Med. 2022;28:1679–1692. doi: 10.1038/s41591-022-01891-3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9419655</ArticleId><ArticleId IdType="pubmed">35915156</ArticleId></ArticleIdList></Reference><Reference><Citation>Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, Weeks EM, Wang M, Hindy G, Zhou W, et al. ; Biobank Japan. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. Nat Genet. 2022;54:1803–1815. doi: 10.1038/s41588-022-01233-6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9729111</ArticleId><ArticleId IdType="pubmed">36474045</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra A, Malik R, Hachiya T, Jürgenson T, Namba S, Posner DC, Kamanu FK, Koido M, Le Grand Q, Shi M, et al. ; COMPASS Consortium. Stroke genetics informs drug discovery and risk prediction across ancestries. Nature. 2022;611:115–123. doi: 10.1038/s41586-022-05165-3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9524349</ArticleId><ArticleId IdType="pubmed">36180795</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira E, Felipe S, de Freitas R, Araújo V, Soares P, Ribeiro J, Henrique Dos Santos L, Alves JO, Canabrava N, van Tilburg M, et al. . ABO blood group and link to COVID-19: a comprehensive review of the reported associations and their possible underlying mechanisms. Microb Pathog. 2022;169:105658. doi: 10.1016/j.micpath.2022.105658</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9233352</ArticleId><ArticleId IdType="pubmed">35764188</ArticleId></ArticleIdList></Reference><Reference><Citation>Beutner F, Teupser D, Gielen S, Holdt LM, Scholz M, Boudriot E, Schuler G, Thiery J. Rationale and design of the Leipzig (LIFE) Heart Study: phenotyping and cardiovascular characteristics of patients with coronary artery disease. PLoS One. 2011;6:e29070. doi: 10.1371/journal.pone.0029070</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245257</ArticleId><ArticleId IdType="pubmed">22216169</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel RS, Schmidt AF, Tragante V, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, et al. ; CARDIoGRAMPlusC4D Consortium. Association of chromosome 9p21 with subsequent coronary heart disease events. Circ Genom Precis Med. 2019;12:e002471. doi: 10.1161/CIRCGEN.119.002471</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6625876</ArticleId><ArticleId IdType="pubmed">30897348</ArticleId></ArticleIdList></Reference><Reference><Citation>Zong X, Wang X, Liu Y, Li Z, Wang W, Wei D, Chen Z. Antiplatelet therapy for patients with COVID-19: systematic review and meta-analysis of observational studies and randomized controlled trials. Front Med. 2022;9:965790. doi: 10.3389/fmed.2022.965790</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9490267</ArticleId><ArticleId IdType="pubmed">36160149</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokolski M, Reszka K, Adamik B, Kilis-Pstrusinska K, Lis W, Pomorski M, Sokolowski J, Doroszko A, Madziarska K, Jankowska EA, et al. . Antiplatelet therapy prior to COVID-19 infection impacts on patients mortality: a propensity score-matched cohort study. Sci Rep. 2024;14:4832. doi: 10.1038/s41598-024-55407-9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10899234</ArticleId><ArticleId IdType="pubmed">38413716</ArticleId></ArticleIdList></Reference><Reference><Citation>Connors JM, Brooks MM, Sciurba FC, Krishnan JA, Bledsoe JR, Kindzelski A, Baucom AL, Kirwan B-A, Eng H, Martin D, et al. ; ACTIV-4B Investigators. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial. JAMA. 2021;326:1703–1712. doi: 10.1001/jama.2021.17272</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8506296</ArticleId><ArticleId IdType="pubmed">34633405</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradbury CA, Lawler PR, Stanworth SJ, McVerry BJ, McQuilten Z, Higgins AM, Mouncey PR, Al-Beidh F, Rowan KM, Berry LR, et al. ; REMAP-CAP Writing Committee for the REMAP-CAP Investigators. Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2022;327:1247–1259. doi: 10.1001/jama.2022.2910</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8941448</ArticleId><ArticleId IdType="pubmed">35315874</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022;399:143–151. doi: 10.1016/S0140-6736(21)01825-0</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8598213</ArticleId><ArticleId IdType="pubmed">34800427</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger JS, Kornblith LZ, Gong MN, Reynolds HR, Cushman M, Cheng Y, McVerry BJ, Kim KS, Lopes RD, Atassi B, et al. ; ACTIV-4a Investigators. Effect of P2Y12 inhibitors on survival free of organ support among non-critically ill hospitalized patients with COVID-19: a randomized clinical trial. JAMA. 2022;327:227–236. doi: 10.1001/jama.2021.23605</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8767444</ArticleId><ArticleId IdType="pubmed">35040887</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohula EA, Berg DD, Lopes MS, Connors JM, Babar I, Barnett CF, Chaudhry S-P, Chopra A, Ginete W, Ieong MH, et al. ; COVID-PACT Investigators. Anticoagulation and antiplatelet therapy for prevention of venous and arterial thrombotic events in critically ill patients with COVID-19: COVID-PACT. Circulation. 2022;146:1344–1356. doi: 10.1161/CIRCULATIONAHA.122.061533</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9624238</ArticleId><ArticleId IdType="pubmed">36036760</ArticleId></ArticleIdList></Reference><Reference><Citation>Duo H, Jin M, Yang Y, Baheti R, Feng Y, Fu Z, Jiang Y, Zheng L, Wan J, Pan H. Effect of antiplatelet therapy after COVID-19 diagnosis: a systematic review with meta-analysis and trial sequential analysis. PLoS One. 2024;19:e0297628. doi: 10.1371/journal.pone.0297628</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10833506</ArticleId><ArticleId IdType="pubmed">38300975</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, Cariou A, Um SL, Utterback B, Laterre P-F, Dhainaut J-F; PROWESS Sepsis Study Group. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit Care. 2004;8:R82–R90. doi: 10.1186/cc2459</Citation><ArticleIdList><ArticleId IdType="pmc">PMC420030</ArticleId><ArticleId IdType="pubmed">15025782</ArticleId></ArticleIdList></Reference><Reference><Citation>Beristain-Covarrubias N, Perez-Toledo M, Thomas MR, Henderson IR, Watson SP, Cunningham AF. Understanding infection-induced thrombosis: lessons learned from animal models. Front Immunol. 2019;10:2569. doi: 10.3389/fimmu.2019.02569</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6848062</ArticleId><ArticleId IdType="pubmed">31749809</ArticleId></ArticleIdList></Reference><Reference><Citation>Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611–2618. doi: 10.1056/NEJMoa041747</Citation><ArticleIdList><ArticleId IdType="pubmed">15602021</ArticleId></ArticleIdList></Reference><Reference><Citation>Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet. 2006;367:1075–1079. doi: 10.1016/S0140-6736(06)68474-2</Citation><ArticleIdList><ArticleId IdType="pubmed">16581406</ArticleId></ArticleIdList></Reference><Reference><Citation>Clayton TC, Gaskin M, Meade TW. Recent respiratory infection and risk of venous thromboembolism: case-control study through a general practice database. Int J Epidemiol. 2011;40:819–827. doi: 10.1093/ije/dyr012</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3147071</ArticleId><ArticleId IdType="pubmed">21324940</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalager-Pedersen M, Sogaard M, Schonheyder HC, Nielsen H, Thomsen RW. Risk for myocardial infarction and stroke after community-acquired bacteremia: a 20-year population-based cohort study. Circulation. 2014;129:1387–1396. doi: 10.1161/CIRCULATIONAHA.113.006699</Citation><ArticleIdList><ArticleId IdType="pubmed">24523433</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–1418. doi: 10.1016/S0140-6736(20)30937-5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Nauffal V, Achanta A, Goldhaber SZ, Piazza G. Association of ABO blood group type with cardiovascular events in COVID-19. J Thromb Thrombolysis. 2021;51:584–586. doi: 10.1007/s11239-020-02364-5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7810281</ArticleId><ArticleId IdType="pubmed">33452583</ArticleId></ArticleIdList></Reference><Reference><Citation>Zietz M, Zucker J, Tatonetti NP. Associations between blood type and COVID-19 infection, intubation, and death. Nat Commun. 2020;11:5761. doi: 10.1038/s41467-020-19623-x</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7666188</ArticleId><ArticleId IdType="pubmed">33188185</ArticleId></ArticleIdList></Reference><Reference><Citation>Latz CA, DeCarlo C, Boitano L, Png CYM, Patell R, Conrad MF, Eagleton M, Dua A. Blood type and outcomes in patients with COVID-19. Ann Hematol. 2020;99:2113–2118. doi: 10.1007/s00277-020-04169-1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7354354</ArticleId><ArticleId IdType="pubmed">32656591</ArticleId></ArticleIdList></Reference><Reference><Citation>Velavan TP, Pallerla SR, Ruter J, Augustin Y, Kremsner PG, Krishna S, Meyer CG. Host genetic factors determining COVID-19 susceptibility and severity. EBioMedicine. 2021;72:103629. doi: 10.1016/j.ebiom.2021.103629</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8512556</ArticleId><ArticleId IdType="pubmed">34655949</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeberg H, Paabo S. The major genetic risk factor for severe COVID-19 is inherited from Neanderthals. Nature. 2020;587:610–612. doi: 10.1038/s41586-020-2818-3</Citation><ArticleIdList><ArticleId IdType="pubmed">32998156</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers TA, Chanock SJ, Machiela MJ. LDlinkR: an R package for rapidly calculating linkage disequilibrium statistics in diverse populations. Front Genet. 2020;11:157. doi: 10.3389/fgene.2020.00157</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7059597</ArticleId><ArticleId IdType="pubmed">32180801</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasela S, Daniloski Z, Bollepalli S, Jordan TX, tenOever BR, Sanjana NE, Lappalainen T. Integrative approach identifies SLC6A20 and CXCR6 as putative causal genes for the COVID-19 GWAS signal in the 3p21.31 locus. Genome Biol. 2021;22:242. doi: 10.1186/s13059-021-02454-4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8381345</ArticleId><ArticleId IdType="pubmed">34425859</ArticleId></ArticleIdList></Reference><Reference><Citation>Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, McMahon A, Morales J, Mountjoy E, Sollis E, et al. . The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 2019;47:D1005–D1012. doi: 10.1093/nar/gky1120</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323933</ArticleId><ArticleId IdType="pubmed">30445434</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasan SK, Rostgaard K, Majeed A, Ullum H, Titlestad K-E, Pedersen OBV, Erikstrup C, Nielsen KR, Melbye M, Nyrén O, et al. . ABO blood group and risk of thromboembolic and arterial disease: a study of 1.5 million blood donors. Circulation. 2016;133:1449–57; discussion 1457. doi: 10.1161/CIRCULATIONAHA.115.017563</Citation><ArticleIdList><ArticleId IdType="pubmed">26939588</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>